Cellectar Biosciences Stock Current Ratio

CLRB Stock  USD 0.30  0.98  76.27%   
Cellectar Biosciences fundamentals help investors to digest information that contributes to Cellectar Biosciences' financial success or failures. It also enables traders to predict the movement of Cellectar Stock. The fundamental analysis module provides a way to measure Cellectar Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cellectar Biosciences stock.
Last ReportedProjected for Next Year
Current Ratio 0.81  0.77 
As of December 11, 2024, Current Ratio is expected to decline to 0.77.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cellectar Biosciences Company Current Ratio Analysis

Cellectar Biosciences' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Cellectar Biosciences Current Ratio

    
  4.51 X  
Most of Cellectar Biosciences' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectar Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cellectar Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Cellectar Biosciences is extremely important. It helps to project a fair market value of Cellectar Stock properly, considering its historical fundamentals such as Current Ratio. Since Cellectar Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectar Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectar Biosciences' interrelated accounts and indicators.
0.95-0.99-0.380.110.030.990.380.44-0.2-0.31-0.24-0.530.37-0.10.91-0.440.630.760.91-0.560.77
0.95-0.95-0.1-0.19-0.30.930.390.2-0.11-0.19-0.16-0.410.23-0.380.78-0.290.450.90.97-0.340.69
-0.99-0.950.38-0.080.0-1.0-0.34-0.440.130.260.180.55-0.40.12-0.920.47-0.66-0.78-0.920.57-0.75
-0.38-0.10.38-0.87-0.82-0.420.11-0.810.350.490.350.67-0.58-0.7-0.650.74-0.860.17-0.030.87-0.22
0.11-0.19-0.08-0.870.870.14-0.120.62-0.21-0.3-0.17-0.40.230.890.38-0.530.6-0.51-0.28-0.670.16
0.03-0.30.0-0.820.870.05-0.090.68-0.27-0.34-0.25-0.30.430.880.27-0.420.49-0.52-0.3-0.620.14
0.990.93-1.0-0.420.140.050.330.47-0.15-0.28-0.19-0.570.4-0.080.93-0.490.670.750.9-0.60.75
0.380.39-0.340.11-0.12-0.090.330.140.040.130.040.22-0.2-0.10.280.40.010.460.45-0.110.26
0.440.2-0.44-0.810.620.680.470.14-0.11-0.21-0.12-0.360.550.550.6-0.40.740.010.2-0.880.29
-0.2-0.110.130.35-0.21-0.27-0.150.04-0.110.970.990.51-0.38-0.12-0.210.36-0.250.02-0.030.18-0.07
-0.31-0.190.260.49-0.3-0.34-0.280.13-0.210.970.970.68-0.51-0.16-0.380.58-0.42-0.04-0.110.33-0.11
-0.24-0.160.180.35-0.17-0.25-0.190.04-0.120.990.970.54-0.43-0.08-0.250.39-0.29-0.05-0.090.2-0.08
-0.53-0.410.550.67-0.4-0.3-0.570.22-0.360.510.680.54-0.59-0.17-0.70.92-0.76-0.22-0.340.59-0.28
0.370.23-0.4-0.580.230.430.4-0.20.55-0.38-0.51-0.43-0.590.230.53-0.60.640.140.24-0.540.21
-0.1-0.380.12-0.70.890.88-0.08-0.10.55-0.12-0.16-0.08-0.170.230.18-0.290.44-0.65-0.43-0.480.13
0.910.78-0.92-0.650.380.270.930.280.6-0.21-0.38-0.25-0.70.530.18-0.660.840.560.72-0.730.6
-0.44-0.290.470.74-0.53-0.42-0.490.4-0.40.360.580.390.92-0.6-0.29-0.66-0.76-0.08-0.210.61-0.21
0.630.45-0.66-0.860.60.490.670.010.74-0.25-0.42-0.29-0.760.640.440.84-0.760.220.39-0.850.39
0.760.9-0.780.17-0.51-0.520.750.460.010.02-0.04-0.05-0.220.14-0.650.56-0.080.220.94-0.10.42
0.910.97-0.92-0.03-0.28-0.30.90.450.2-0.03-0.11-0.09-0.340.24-0.430.72-0.210.390.94-0.30.69
-0.56-0.340.570.87-0.67-0.62-0.6-0.11-0.880.180.330.20.59-0.54-0.48-0.730.61-0.85-0.1-0.3-0.35
0.770.69-0.75-0.220.160.140.750.260.29-0.07-0.11-0.08-0.280.210.130.6-0.210.390.420.69-0.35
Click cells to compare fundamentals

Cellectar Current Ratio Historical Pattern

Today, most investors in Cellectar Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cellectar Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cellectar Biosciences current ratio as a starting point in their analysis.
   Cellectar Biosciences Current Ratio   
       Timeline  
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

Cellectar Price To Sales Ratio

Price To Sales Ratio

(1,046.18)

At present, Cellectar Biosciences' Price To Sales Ratio is projected to decrease significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Cellectar Biosciences has a Current Ratio of 4.51 times. This is 54.98% higher than that of the Biotechnology sector and 35.57% lower than that of the Health Care industry. The current ratio for all United States stocks is 108.8% lower than that of the firm.

Cellectar Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectar Biosciences' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics of similar companies.
Cellectar Biosciences is currently under evaluation in current ratio category among its peers.

Cellectar Fundamentals

About Cellectar Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cellectar Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:
Check out Cellectar Biosciences Piotroski F Score and Cellectar Biosciences Altman Z Score analysis.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.41)
Return On Assets
(1.66)
Return On Equity
(7.97)
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.